- Home
- CQP vs INM Comparison
CQP vs INM Comparison
Compare CQP & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CQP | INM |
|---|---|---|
| Founded | 2003 | 1981 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2B | 3.6M |
| IPO Year | 2007 | N/A |
Fundamental Metrics
Financial Performance| Metric | CQP | INM |
|---|---|---|
| Price | $59.44 | $0.88 |
| Analyst Decision | Strong Sell | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $53.33 | N/A |
| AVG Volume (30 Days) | ★ 89.8K | 64.2K |
| Earning Date | 02-20-2026 | 02-05-2026 |
| Dividend Yield | ★ 5.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.84 | N/A |
| Revenue | ★ $10,308,000,000.00 | $4,506,597.00 |
| Revenue This Year | $24.39 | N/A |
| Revenue Next Year | $4.31 | N/A |
| P/E Ratio | $14.91 | ★ N/A |
| Revenue Growth | ★ 15.43 | N/A |
| 52 Week Low | $49.53 | $0.89 |
| 52 Week High | $68.42 | $7.98 |
Technical Indicators
Market Signals| Indicator | CQP | INM |
|---|---|---|
| Relative Strength Index (RSI) | 59.81 | 32.56 |
| Support Level | $56.35 | $0.90 |
| Resistance Level | $59.45 | $1.09 |
| Average True Range (ATR) | 1.26 | 0.06 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 63.55 | 0.00 |
Price Performance
Historical ComparisonAbout CQP Cheniere Energy Partners LP
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.
About INM InMed Pharmaceuticals Inc.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.